Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Richeldi (Rome, Italy), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), B. Crestani (Paris, France), M. Molina Molina (Barcelona, Spain), R. Goeldner (Biberach, Germany), S. Stowasser (Ingelheim am Rhein, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), Y. Inoue (Sakai City, Osaka, Japan). Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib?. 740

Member's Comments

No comment yet.

Related content which might interest you: Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 Are there patient characteristics associated with improvements or worsening in the placebo arm of COPD tlinical trials? Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 A network analysis of clinical characteristics of patients with COPD: partial results. Source: International Congress 2018 – Chronic respiratory disease: effects of rehabilitation interventions in patients Year: 2018 Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 Patients with persistent asthma may have poor disease control despite normal lung function: baseline data from a pan-European real-life study Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009 A real life multicenter national study on the use of nintedanib in moderate to severe IPF patients Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Case-control study on risk factors to COPD – does the sampling of the cases and controls affect the results? Source: Annual Congress 2008 - Epidemiology of respiratory symptoms and COPD Year: 2008 Do changes in spirometric indices and FeNO predict asthma outcomes in children? An individual patient data analysis using results from seven FeNO trials Source: International Congress 2018 – Primary ciliary dyskinesia and lung function tests in respiratory morbidities Year: 2018 Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study) Source: Eur Respir J , 49 (3) 1501885; DOI: 10.1183/13993003.01885-2015 Year: 2017 Real-world exacerbation rates in Japanese patients with COPD: results from the EXACOS observational cohort study Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021 Do exacerbation outcomes in the POET-COPDÔ trial differ between regions? Source: Annual Congress 2011 - COPD exacerbation Year: 2011 Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD) Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020 Treatment patterns in stable COPD patients – results from a large observational European study (SPACE) Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019 Patterns of discontinuation in patients with IPF treated with open-label nintedanib: data from INPULSIS-ON Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 EXACTLE-Trial: Main results. How can EXACTLE help in AATD patients' treatment? Source: Annual Congress 2008 - EXACTLE: EXAcerbations and CT scans as Lung Endpoints in Alpha-1-Antitrypsin Deficiency Year: 2008 Evidence generation for the clinical impact of myCOPD in patients with mild, moderate and newly diagnosed COPD: a randomised controlled trial Source: ERJ Open Res, 6 (4) 00460-2020; 10.1183/23120541.00460-2020 Year: 2020